deoxycytidine has been researched along with Chronic Hepatitis C in 27 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (3.70) | 29.6817 |
2010's | 26 (96.30) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Cotler, SJ; Dahari, H; Guedj, J; Layden, TJ; Nettles, RE; Perelson, AS; Rong, L; Sansone, ND; Uprichard, SL | 1 |
Harrison, SA; Torres, DM | 1 |
Baronas, V; Haines, K; Klumpp, K; Le Pogam, S; Li, L; Nájera, I; Piso, K; So, SS; Tong, X; Yan, JM | 1 |
Ackrill, A; Badman, E; Bernaards, C; Chan, A; Chen, YC; Kulkarni, R; Moreira, S; Smith, PF; Thommes, J; Zhu, Y | 1 |
Haines, K; Li, L; Najera, I; Tong, X | 1 |
Brennan, B; Canini, L; Chatterjee, A; Guedj, J; Lemenuel-Diot, A; Perelson, AS; Smith, PF | 1 |
Brunda, M; Chu, T; Elston, R; Gane, EJ; George, J; Glavini, K; Hammond, JM; Jensen, DM; Le Pogam, S; Nájera, I; Passe, S; Piekarska, A; Rodriguez, I; Zeuzem, S | 1 |
Canini, L; Chatterjee, A; Guedj, J; Lemenuel-Diot, A; Perelson, AS; Smith, PF | 1 |
Ahmadyar, S; Babusis, D; Barauskas, O; Feng, JY; McCutcheon, K; Park, Y; Perron, M; Perry, JK; Ray, AS; Sakowicz, R; Schultz, BE; Stepan, G; Xu, Y; Yu, H | 1 |
Forns, X; Hézode, C; Le Pogam, S; Lee, SS; Nájera, I; Scalori, A; Thommes, JA; Voulgari, A; Wedemeyer, H | 1 |
Barreiro, P; Collado, A; de Los Santos Gil, I; González-Serrano, M; Hernández-Burruezo, JJ; López-Cortés, LF; López-Ruz, MA; Macías, J; Martín-Rico, P; Merino, D; Mira, JA; Muñoz, L; Pineda, JA; Ríos-Villegas, MJ; Rivero, A; Soriano, V; Torres-Tortosa, M; Tural, C; Viciana, P | 1 |
Floridia, M; Manconi, PE; Ortu, F; Weimer, LE | 1 |
Berrey, M; Cammack, N; De La Rosa, A; Ewing, A; Kang, H; Kosaka, A; Le Pogam, S; Nájera, I; Seshaadri, A; Symonds, B; Yan, JM | 1 |
Thomas, DL | 1 |
Angus, PW; Baher, L; Berrey, MM; Bradford, W; Chu, T; Elston, R; Gane, EJ; Ipe, D; Laughlin, M; Lopatin, U; Morcos, PN; Najera, I; Ritchie, B; Roberts, SK; Shulman, NS; Smith, PF; Stedman, CA | 1 |
Ghany, MG; Seeff, LB | 1 |
Angus, PW; Chu, TW; Elston, R; Gane, EJ; Germer, S; Iglesias, VA; Ipe, D; Kulkarni, R; Lopatin, U; Lu, XY; Ritchie, B; Roberts, SK; Shulman, NS; Smith, PF; Stedman, C | 1 |
Jacobson, I; Najera, I; Pawlotsky, JM | 1 |
Gao, M; Lin, K; Liu, Q; Villareal, VA; Yang, PL | 1 |
Naggie, S; Sulkowski, MS | 1 |
Ali, S; Chhabra, M; Chin, DJ; Ilnicka, M; Kang, H; Klumpp, K; Kosaka, A; Le Pogam, S; Nájera, I; Shulman, NS; Smith, P; Yan, JM | 1 |
Gores, GJ; Razumilava, N | 1 |
Agbaji, O; Ekong, E; Graham, C; Hawkins, C; Idoko, J; Kanki, P; Meloni, S; Muazu, M; Murphy, R; Nimzing, L; Sankalé, JL; Thio, CL | 1 |
Cannizzaro, MV; Chimenti, S; Chiricozzi, A; Giunta, A; Nisticò, SP; Saraceno, R | 1 |
Bzowej, N; Chen, YC; Ferenci, P; Herring, R; Ipe, D; Jensen, D; Ma, MM; Munson, ML; Najera, I; Pockros, P; Rodriguez-Torres, M; Thommes, J; Vierling, J; Wedemeyer, H; Zeuzem, S | 1 |
Chen, YC; Cooper, C; Dickson, R; Jensen, D; Kulkarni, R; Lou Munson, M; Najera, I; Pockros, PJ; Ramji, A; Taylor, R; Thommes, J; Tice, A; Tsai, N; Vierling, JM | 1 |
Chen, WC; Hsu, YC; Lee, JC; Lin, CK; Lin, YT; Tseng, CK; Wu, YH | 1 |
6 review(s) available for deoxycytidine and Chronic Hepatitis C
Article | Year |
---|---|
Management of untreated and nonresponder patients with chronic hepatitis C.
Topics: Alcohol Drinking; Antiviral Agents; Biopsy; Decision Making; Deoxycytidine; Disease Management; Disease Progression; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Liver Cirrhosis; Liver Function Tests; Male; Middle Aged; Obesity; Polyethylene Glycols; Practice Patterns, Physicians'; Recombinant Proteins; Retreatment; Ribavirin; RNA, Viral; Treatment Failure; Viral Load; Virus Replication | 2010 |
Resistance to mericitabine, a nucleoside analogue inhibitor of HCV RNA-dependent RNA polymerase.
Topics: Antiviral Agents; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Deoxycytidine; Drug Resistance, Viral; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; RNA-Dependent RNA Polymerase; Treatment Outcome | 2012 |
Anti-HCV drugs in the pipeline.
Topics: Animals; Antiviral Agents; Carbamates; Cyclosporine; Deoxycytidine; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Pyrrolidines; Valine; Virus Replication | 2011 |
Management of patients coinfected with HCV and HIV: a close look at the role for direct-acting antivirals.
Topics: Adenine; Anti-HIV Agents; Antiviral Agents; Coinfection; Deoxycytidine; Dideoxynucleosides; Disease Progression; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Emtricitabine; Hepatitis C, Chronic; HIV Infections; Homosexuality, Male; Humans; Interferon-alpha; Lamivudine; Liver Cirrhosis; Liver Diseases; Male; Oligopeptides; Organophosphonates; Polyethylene Glycols; Proline; Pyrrolidinones; Raltegravir Potassium; Recombinant Proteins; Ribavirin; Serine Proteinase Inhibitors; Substance Abuse, Intravenous; Tenofovir; Treatment Outcome | 2012 |
Classification, diagnosis, and management of cholangiocarcinoma.
Topics: Antineoplastic Agents; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Drug Therapy; Gemcitabine; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Severity of Illness Index; Surgical Procedures, Operative | 2013 |
Complete resolution of erythrodermic psoriasis in an HIV and HCV patient unresponsive to antipsoriatic treatments after highly active antiretroviral therapy (Ritonavir, Atazanavir, Emtricitabine, Tenofovir).
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Hepatitis C, Chronic; HIV Infections; Humans; Immunocompromised Host; Male; Middle Aged; Oligopeptides; Organophosphonates; Psoriasis; Pyridines; Ritonavir; Tenofovir; Treatment Outcome | 2012 |
13 trial(s) available for deoxycytidine and Chronic Hepatitis C
Article | Year |
---|---|
In vivo emergence of a novel mutant L159F/L320F in the NS5B polymerase confers low-level resistance to the HCV polymerase inhibitors mericitabine and sofosbuvir.
Topics: Antiviral Agents; Deoxycytidine; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Mutation; Polyethylene Glycols; Recombinant Proteins; Replicon; Ribavirin; RNA, Viral; Sofosbuvir; Uridine Monophosphate; Viral Nonstructural Proteins | 2014 |
Identification of the NS5B S282T resistant variant and two novel amino acid substitutions that affect replication capacity in hepatitis C virus-infected patients treated with mericitabine and danoprevir.
Topics: Adult; Amino Acid Substitution; Antiviral Agents; Base Sequence; Cyclopropanes; Deoxycytidine; DNA Replication; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Isoindoles; Lactams; Lactams, Macrocyclic; Male; Middle Aged; Molecular Sequence Data; Mutation; Phenotype; Proline; RNA, Viral; Sequence Analysis, DNA; Sulfonamides; Viral Nonstructural Proteins | 2014 |
A pharmacokinetic/viral kinetic model to evaluate the treatment effectiveness of danoprevir against chronic HCV.
Topics: Antiviral Agents; Cyclopropanes; Deoxycytidine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Isoindoles; Lactams; Lactams, Macrocyclic; Models, Theoretical; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Ribavirin; Sulfonamides; Treatment Outcome; Viral Load; Viral Nonstructural Proteins | 2015 |
Interferon-free regimens containing setrobuvir for patients with genotype 1 chronic hepatitis C: a randomized, multicenter study.
Topics: Adult; Antiviral Agents; Australia; Benzothiadiazines; Cyclopropanes; Deoxycytidine; Drug Therapy, Combination; Europe; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Isoindoles; Lactams; Lactams, Macrocyclic; Male; Middle Aged; New Zealand; Phenotype; Proline; Quinolones; Remission Induction; Ribavirin; RNA, Viral; Sulfonamides; Time Factors; Treatment Outcome; United States; Viral Load | 2016 |
Modelling the interaction between danoprevir and mericitabine in the treatment of chronic HCV infection.
Topics: Antiviral Agents; Cyclopropanes; Deoxycytidine; Dose-Response Relationship, Drug; Drug Interactions; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Isoindoles; Lactams; Lactams, Macrocyclic; Models, Biological; Proline; RNA, Viral; Sulfonamides; Viral Load | 2016 |
Mericitabine and Either Boceprevir or Telaprevir in Combination with Peginterferon Alfa-2a plus Ribavirin for Patients with Chronic Hepatitis C Genotype 1 Infection and Prior Null Response: The Randomized DYNAMO 1 and DYNAMO 2 Studies.
Topics: Adult; Antibodies, Viral; Antimetabolites; Antiviral Agents; Deoxycytidine; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome | 2016 |
Efficacy of pegylated interferon plus ribavirin treatment in HIV/hepatitis C virus co-infected patients receiving abacavir plus lamivudine or tenofovir plus either lamivudine or emtricitabine as nucleoside analogue backbone.
Topics: Adenine; Adult; Anti-HIV Agents; Blood; Cohort Studies; Deoxycytidine; Dideoxynucleosides; Emtricitabine; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Male; Middle Aged; Multivariate Analysis; Organophosphonates; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Tenofovir; Treatment Outcome; Viral Load | 2008 |
RG7128 alone or in combination with pegylated interferon-α2a and ribavirin prevents hepatitis C virus (HCV) Replication and selection of resistant variants in HCV-infected patients.
Topics: Amino Acid Substitution; Antiviral Agents; Deoxycytidine; Drug Resistance, Viral; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; New Zealand; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Selection, Genetic; United States; Viral Load; Viral Nonstructural Proteins; Virus Replication | 2010 |
Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial.
Topics: Administration, Oral; Adult; Antiviral Agents; Cyclopropanes; Deoxycytidine; Double-Blind Method; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Isoindoles; Lactams; Lactams, Macrocyclic; Male; Middle Aged; Polyethylene Glycols; Proline; Recombinant Proteins; RNA, Viral; Sulfonamides; Viral Nonstructural Proteins | 2010 |
Effect of IL28B genotype on early viral kinetics during interferon-free treatment of patients with chronic hepatitis C.
Topics: Antiviral Agents; Australia; Cyclopropanes; Deoxycytidine; Double-Blind Method; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Interleukins; Isoindoles; Kinetics; Lactams; Lactams, Macrocyclic; Models, Biological; Models, Statistical; New Zealand; Phenotype; Polymorphism, Single Nucleotide; Proline; RNA, Viral; Sulfonamides; Treatment Outcome; Viral Load; Virus Replication | 2012 |
Characterization of hepatitis C virus (HCV) quasispecies dynamics upon short-term dual therapy with the HCV NS5B nucleoside polymerase inhibitor mericitabine and the NS3/4 protease inhibitor danoprevir.
Topics: Adult; Antiviral Agents; Cyclopropanes; Deoxycytidine; Double-Blind Method; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Enzyme Inhibitors; Hepacivirus; Hepatitis C, Chronic; Humans; Isoindoles; Lactams; Lactams, Macrocyclic; Mutation; Placebos; Proline; RNA, Viral; Sulfonamides; Viral Load; Viral Nonstructural Proteins | 2012 |
PROPEL: a randomized trial of mericitabine plus peginterferon alpha-2a/ribavirin therapy in treatment-naïve HCV genotype 1/4 patients.
Topics: Adolescent; Adult; Aged; Deoxycytidine; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Young Adult | 2013 |
JUMP-C: a randomized trial of mericitabine plus pegylated interferon alpha-2a/ribavirin for 24 weeks in treatment-naïve HCV genotype 1/4 patients.
Topics: Adolescent; Adult; Aged; Canada; Deoxycytidine; Double-Blind Method; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; United States; Young Adult | 2013 |
8 other study(ies) available for deoxycytidine and Chronic Hepatitis C
Article | Year |
---|---|
Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life.
Topics: Adult; Antiviral Agents; Bayes Theorem; Carbamates; Cell Line; Deoxycytidine; Female; Half-Life; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Middle Aged; Models, Biological; Pyrrolidines; RNA, Viral; Valine; Viral Load; Viral Nonstructural Proteins; Virus Assembly | 2013 |
Small steps toward a better treatment for chronic hepatitis C infection: mericitabine, pegylated interferon, and ribavirin in the PROPEL and JUMP-C trials.
Topics: Deoxycytidine; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2013 |
Understanding the effect of the HCV polymerase inhibitor mericitabine on early viral kinetics in the phase 2 JUMP-C and PROPEL studies.
Topics: Adult; Aged; Antiviral Agents; Clinical Trials, Phase II as Topic; Deoxycytidine; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Retrospective Studies; Ribavirin; Treatment Outcome; Young Adult | 2014 |
Role of Mitochondrial RNA Polymerase in the Toxicity of Nucleotide Inhibitors of Hepatitis C Virus.
Topics: Antiviral Agents; Cell Line; Deoxycytidine; DNA Polymerase gamma; DNA-Directed DNA Polymerase; DNA-Directed RNA Polymerases; Guanosine Monophosphate; Hepacivirus; Hepatitis C, Chronic; Humans; Mitochondria; Nucleosides; Oxygen Consumption; Protein Biosynthesis; RNA; RNA, Mitochondrial; Sofosbuvir; Transcription, Genetic; Virus Replication | 2016 |
Raltegravir, tenofovir, and emtricitabine in an HIV-infected patient with HCV chronic hepatitis, NNRTI intolerance and protease inhibitors-induced severe liver toxicity.
Topics: Adenine; Adult; Antiviral Agents; CD4-Positive T-Lymphocytes; Chemical and Drug Induced Liver Injury; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Female; Hepatitis C, Chronic; HIV Infections; Humans; Liver; Lymphocyte Count; Organophosphonates; Protease Inhibitors; Pyrrolidinones; Raltegravir Potassium; Tenofovir; Treatment Outcome; Viral Load | 2010 |
Curing hepatitis C with pills: a step toward global control.
Topics: Administration, Oral; Antiviral Agents; Cyclopropanes; Deoxycytidine; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Isoindoles; Lactams; Lactams, Macrocyclic; Proline; Sulfonamides; Viral Nonstructural Proteins | 2010 |
Impact of hepatitis C virus on HIV response to antiretroviral therapy in Nigeria.
Topics: Adult; Alanine Transaminase; Alkynes; Anti-Retroviral Agents; Benzoxazines; Chemical and Drug Induced Liver Injury; Coinfection; Cyclopropanes; Deoxycytidine; Drug Combinations; Drug Therapy, Combination; Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Lamivudine; Logistic Models; Male; Nevirapine; Nigeria; Organophosphorus Compounds; RNA, Viral; Stavudine; Zidovudine | 2013 |
Green tea phenolic epicatechins inhibit hepatitis C virus replication via cycloxygenase-2 and attenuate virus-induced inflammation.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Catechin; Cell Line, Tumor; Cyclooxygenase 2; Deoxycytidine; Gene Expression; Hepacivirus; Hepatitis C, Chronic; Humans; Inflammation; Interferon-alpha; Interleukin-1beta; Nitric Oxide Synthase Type II; Oligopeptides; RNA, Viral; Stereoisomerism; Tea; Tumor Necrosis Factor-alpha; Virus Replication | 2013 |